Get the Stockscreener App
2.29
2.34%
-0.06
Codexis Inc stock is traded at $2.29, with a volume of 531.80K.
It is down -2.34% in the last 24 hours and down -0.22% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$2.35
Open:
$2.34
24h Volume:
531.80K
Relative Volume:
0.55
Market Cap:
$190.14M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-2.0631
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
-4.38%
1M Performance:
-0.22%
6M Performance:
-49.89%
1Y Performance:
-32.50%
1-Day Range:
$2.25
$2.375
1-Week Range:
$2.25
$2.56
52-Week Range:
$1.90
$6.08
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
2.295 | 203.80M | 70.14M | -76.24M | -57.06M | -1.11 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.48 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.74 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.63 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Opaleye Management Makes a Bold Move with Massive Codexis Stock Purchase - TipRanks
Group One Trading LLC Buys Shares of 15,226 Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis, Inc. (NASDAQ:CDXS) Stake Lifted by Northern Trust Corp - Defense World
Codexis’ Landmark Presentations at TIDES USA Highlight - GlobeNewswire
Transcript : Codexis, Inc.Special Call - marketscreener.com
Codexis (CDXS) Showcases Innovations in siRNA Manufacturing at T - GuruFocus
Codexis (CDXS) Showcases Innovations in siRNA Manufacturing at TIDES USA | CDXS Stock News - GuruFocus
Codexis Highlights Advancements in Eco Synthesis Technology for siRNA Manufacturing at TIDES USA Conference - Nasdaq
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA - GlobeNewswire
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process ... - Bluefield Daily Telegraph
Codexis’ Landmark Presentations at TIDES USA Highlight Reproducibility and Process Simplification of the ECO Synthesis Platform for Manufacturing siRNA - GlobeNewswire Inc.
Codexis to Participate in Jefferies Global Healthcare Conference - GuruFocus
Codexis to Participate in Jefferies Global Healthcare Conference | CDXS Stock News - GuruFocus
Argan Strengthens Board with Energy Giant Sempra Executive: Strategic Growth Move - Stock Titan
Codexis’s SWOT analysis: innovative enzyme firm’s stock poised for growth - Investing.com Australia
Codexis’s SWOT analysis: innovative enzyme firm’s stock poised for growth By Investing.com - Investing.com Canada
Former Genentech and Codexis Legal Leader Takes Top Legal Role at Liver Disease Biotech Aligos - Stock Titan
Codexis, Inc. (NASDAQ:CDXS) Shares Bought by Ameriprise Financial Inc. - Defense World
Cantor Fitzgerald Lowers Earnings Estimates for Codexis - Defense World
Codexis (NASDAQ:CDXS) Stock Rating Upgraded by StockNews.com - Defense World
Price T Rowe Associates Inc. MD Boosts Stock Position in Codexis, Inc. (NASDAQ:CDXS) - Defense World
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Earnings: Here's What Analysts Think - Yahoo Finance
Codexis, Inc. (NASDAQ:CDXS) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
Codexis, Inc. (NASDAQ:CDXS) Q1 2025 Earnings Call Transcript - Insider Monkey
Codexis, Inc. (NASDAQ:CDXS) Shares Sold by Stifel Financial Corp - Defense World
Codexis Earnings Call: Strategic Growth Amid Challenges - TipRanks
Codexis reiterates $64M-$68M 2025 revenue guidance as ecosynthesis platform gains traction with CDMOs - MSN
Stifel maintains Buy rating on Codexis stock with $5 target By Investing.com - Investing.com India
Stifel maintains Buy rating on Codexis stock with $5 target - Investing.com
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with Strategic Growth Initiatives - GuruFocus
Codexis Inc (CDXS) Q1 2025 Earnings: EPS at -$0.23 and Revenue H - GuruFocus
Codexis Inc (CDXS) Q1 2025 Earnings Call Highlights: Navigating Revenue Volatility with ... - Yahoo Finance
Codexis Reports Q1 2025 Financial Results and Strategic Progress - TipRanks
Codexis: Q1 Earnings Snapshot - MySA
Earnings call transcript: Codexis Q1 2025 results miss forecasts, stock declines - Investing.com Nigeria
Codexis (CDXS) Navigates Q1 Revenue Challenges, Confirms 2025 Ou - GuruFocus
Codexis, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:CDXS) - Seeking Alpha
Codexis (CDXS) Projects Financial Stability Until 2026 | CDXS St - GuruFocus
Codexis (CDXS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Codexis (CDXS) Reports Lower Than Expected Q1 Revenue, Affirms 2 - GuruFocus
Codexis Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Codexis May 2025 presentation slides: RNA manufacturing pivot targets path to profitability - Investing.com Australia
Codexis (CDXS) Projects Financial Stability Until 2026 | CDXS Stock News - GuruFocus
CODEXIS Earnings Results: $CDXS Reports Quarterly Earnings - Nasdaq
Codexis (CDXS) Reports Lower Than Expected Q1 Revenue, Affirms 2025 Outlook | CDXS Stock News - GuruFocus
Codexis Reports First Quarter 2025 Financial Results - The Manila Times
Codexis Secures Landmark ECO Synthesis Deal as Q1 Earnings Show Strategic Pivot to RNA Manufacturing - Stock Titan
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Codexis Inc Stock (CDXS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
May 28 '25 |
Buy |
2.36 |
5,000 |
11,800 |
12,000,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 30 '25 |
Buy |
2.31 |
25,000 |
57,660 |
9,655,000 |
| Opaleye Management Inc. | 10% Owner |
May 01 '25 |
Buy |
2.32 |
20,000 |
46,436 |
9,675,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 25 '25 |
Buy |
2.24 |
25,000 |
55,915 |
9,630,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 16 '25 |
Buy |
2.13 |
70,000 |
148,890 |
9,560,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 17 '25 |
Buy |
2.09 |
45,000 |
94,162 |
9,605,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 15 '25 |
Buy |
2.23 |
25,000 |
55,720 |
9,490,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 08 '25 |
Buy |
1.98 |
100,000 |
198,380 |
9,465,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 03 '25 |
Buy |
2.30 |
75,000 |
172,740 |
9,365,000 |
| Opaleye Management Inc. | 10% Owner |
Apr 01 '25 |
Buy |
2.48 |
35,000 |
86,772 |
9,285,000 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):